[go: up one dir, main page]

WO2025021972A1 - Dérivé d'exopolysaccharide bactérien marin présentant des propriétés anticancéreuses et ses utilisations - Google Patents

Dérivé d'exopolysaccharide bactérien marin présentant des propriétés anticancéreuses et ses utilisations Download PDF

Info

Publication number
WO2025021972A1
WO2025021972A1 PCT/EP2024/071243 EP2024071243W WO2025021972A1 WO 2025021972 A1 WO2025021972 A1 WO 2025021972A1 EP 2024071243 W EP2024071243 W EP 2024071243W WO 2025021972 A1 WO2025021972 A1 WO 2025021972A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
sulfated
over
eps
kda
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2024/071243
Other languages
English (en)
Inventor
Sylvia Colliec-Jouault
Corinne Sinquin
Agata ZYKWINSKA
Dominique Heymann
Javier MUNOZ GARCIA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut Francais de Recherche pour lExploitation de la Mer (IFREMER)
Universite de Nantes
Institut National de la Sante et de la Recherche Medicale INSERM
INSTITUT DE CANCEROLOGIE DE L'OUEST
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut Francais de Recherche pour lExploitation de la Mer (IFREMER)
Universite de Nantes
Institut National de la Sante et de la Recherche Medicale INSERM
INSTITUT DE CANCEROLOGIE DE L'OUEST
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Institut Francais de Recherche pour lExploitation de la Mer (IFREMER), Universite de Nantes, Institut National de la Sante et de la Recherche Medicale INSERM, INSTITUT DE CANCEROLOGIE DE L'OUEST filed Critical Centre National de la Recherche Scientifique CNRS
Publication of WO2025021972A1 publication Critical patent/WO2025021972A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • Cancer is among the leading causes of mortality in developed countries.
  • Current major treatments for cancer management include surgery, cytotoxic chemotherapy, targeted therapy, radiation therapy, endocrine therapy, and immunotherapy.
  • cytotoxic chemotherapy Despite the endeavors and achievements made in treating cancers during the past decades, disease recurrence and progression remain a major obstacle to therapy.
  • Drug resistance exists in two forms: acquired resistance, where the drug is initially efficient but becomes ineffective over time; and intrinsic resistance, which occurs when a drug is ineffective from the beginning of treatment.
  • Many strategies have been designed to combat drug resistance, either by combining the currently available therapies or by developing novel therapies. While the focus is shifting to the development and application of novel therapeutic agents for immunotherapy and targeted therapy, chemotherapy is still standard-of-care in the treatment of most cancers and new and effective chemotherapeutic agents are still needed.
  • mimetics are often less anticoagulant than heparin and heparan sulfate but they maintain some of their benefits in suppressing cancer growth and metastasis through their weak anticoagulant activity by inhibiting thrombin generation, fibrin formation but also heparanase (enzyme involved in heparan sulfate metabolism and turnover) (Sasisekharan et al., Nat. Rev. Cancer, 2002, 2: 521-528; Bobek and Kovarik, Biomedicine & Pharmacotherapy, 2004, 58: 213-219). These mimetics via a multi-target mechanism of action have inhibitory effects on heparinase, selectins, growth factor receptor signaling with limited side effects.
  • Sulfated oligosaccharides have been studied, such as a sulfated form of phosphomannopentaose and phosphomannotetraose named PI-88 but also a sulfated tetrasaccharide derivative named PG545 (Lanzi & Cassinelli, Molecules, 2018, 23(11): 2915; Ferro et al., Carbohydr. Res., 2001, 332: 183-189); and a sulfated form of maltohexose and sulfated maltotriose (Vismara et al., Molecules, 2012, 17: 9912-9930).
  • Two polysaccharides extracted from Prunella vulgaris L. have also been described for their anti-lung adenocarcinoma activity (Feng et al., Molecules, 2010, 15: 5096-5103).
  • polysaccharides from different sources can share some biological properties with glycosaminoglycans (GAGs), and especially heparan sulfate or heparin, without exhibiting the same bleeding risks and with a low risk of contamination by a non- conventional transmissible agent such as prions or emerging viruses due to a large “species-barrier” (DeAngelis, Appl. Microbiol. Biotechnol., 2012, 94: 295-305).
  • GAGs glycosaminoglycans
  • heparan sulfate or heparin without exhibiting the same bleeding risks and with a low risk of contamination by a non- conventional transmissible agent such as prions or emerging viruses due to a large “species-barrier”
  • Marine bacteria associated with deep-sea hydrothermal conditions have demonstrated their ability to produce, in an aerobic carbohydrate-based medium, unusual extracellular polymers. They present original structural features that can be modified to design bioactive compounds and improve their specificity (Rehm et al. , Rev. Microbiol., 2010, 8: 578-592; Colliec-Jouault et al., Handbook of Exp. Pharmacol., 2012, 423-449).
  • MAP4 over-sulfated polysaccharide
  • EPS marine native exopolysaccharide
  • infeman excreted by the Alteromonas infernus strain
  • MAP4 strongly inhibits tumor growth with no apparent toxicity.
  • MAP4 in combination with doxorubicin inhibits the viability of cells from osteosarcoma, lung cancer, and colon cancer cell lines to a greater extent than MAP4 alone, while the MAPI /doxorubicin combination does not exhibit such an additive effect.
  • the present invention relates to a 50-60 kDa oversulfated exopolysaccharide (EPS) for use in the prevention or treatment of cancer in a subject, wherein said 50-60 kDa over-sulfated EPS is obtained by a method comprising:
  • a subsequent step consisting of sulfation of the depolymerized EPS to obtain an over- sulfated depolymerized EPS comprising adding to the depolymerized EPS at least one sulfation agent in an amount sufficient to obtain an oversulfated exopolysaccharide having a degree of sulfate-group substitution of between 35% and 45% by weight relative to the total weight of the over-sulfated depolymerized EPS, preferably about 40% by weight relative to the total weight of the over- sulfated depolymerized EPS; and
  • a subsequent step consisting of isolating the 50-60 kDa over-sulfated EPS from the over-sulfated depolymerized EPS, wherein the 50-60 kDa over-sulfated EPS has a molecular weight of about 60,000 g/mol, and a polydispersity index lower than 5, preferably comprised between 1,5 and 4, more preferably lower than 2.
  • the step of isolating the 50-60 kDa over-sulfated EPS from the over- sulfated depolymerized EPS is carried out by fractionation, in particular fractionation performed by size exclusion chromatography.
  • the 50-60 kDa over-sulfated EPS is a 50-60 kDa over-sulfated EPS having a molecular weight of about 60,000 g/mol, a polydispersity index lower than 2, and a degree of sulfate-group substitution of 40% by weight relative to the total weight of the over-sulfated depolymerized EPS.
  • the cancer of the patient may belong to the group consisting of carcinoma, lymphoma, blastoma, sarcoma, and leukemia.
  • the cancer may belong to the group consisting of bone cancer, lung cancer, liver cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, colon cancer, breast cancer, carcinoma of the sexual and reproductive organs (e.g., prostate cancer, uterine cancer, etc.), Hodgkin’s Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the bladder, cancer of the kidney, renal cell carcinoma, carcinoma of the pelvis, neoplasms of the central nervous system (CNS), neuroectodermal cancer, spinal axis tumors,
  • the cancer is a solid malignant tumor.
  • the solid cancer may be selected from the group consisting of osteosarcoma, non-small cell lung cancer, melanoma, colon cancer and breast cancer.
  • the solid cancer is osteosarcoma, non-small cell lung cancer, melanoma or colon cancer.
  • the cancer is a metastatic cancer.
  • the present invention relates to a method for treating cancer in a subject, the method comprising a step of administering to said subject in need thereof a therapeutically effective amount of a 50-60 kDa over-sulfated EPS as defined herein.
  • the 50-60 kDa over-sulfated EPS may be a 50-60 kDa over-sulfated EPS having a molecular weight of about 60,000 g/mol, a polydispersity index lower than 2, and a degree of sulfate-group substitution of 40% by weight relative to the total weight of the over-sulfated depolymerized EPS.
  • the subject is a cancer patient, as described above.
  • the cancer to be treated is as described above.
  • the present invention relates to a drug combination for use in the prevention or treatment of a cancer in a subject, wherein the drug combination comprises a 50-60 kDa over-sulfated EPS as defined herein and an anticancer agent.
  • the 50-60 kDa over-sulfated EPS may be a 50-60 kDa over-sulfated EPS having a molecular weight of about 60,000 g/mol, a polydispersity index lower than 2, and a degree of sulfate-group substitution of 40% by weight relative to the total weight of the over-sulfated depolymerized EPS.
  • the anticancer agent is a topoisomerase II inhibitor, in particular a topoisomerase II poison, for example an intercalating topoisomerase II poison or a non-intercalating topoisomerase II poison.
  • the anticancer agent is DNA intercalating agent.
  • the DNA intercalating agent belongs to the anthracycline family.
  • the DNA intercalating agent is doxorubicin.
  • the subject to be treated with a drug combination described herein is a cancer patient, as described above.
  • the cancer to be prevented or treated is as described above.
  • the cancer may be a solid malignant tumor selected from the group consisting of osteosarcoma, non-small cell lung cancer, colon cancer and breast cancer.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising an effective amount of a 50-60 kDa over-sulfated EPS as defined herein, or of a drug combination as defined herein, and at least one pharmaceutically acceptable carrier or excipient for use in the prevention or treatment of cancer in a subject.
  • the 50-60 kDa over-sulfated EPS may be a 50-60 kDa over-sulfated EPS having a molecular weight of about 60,000 g/mol, a polydispersity index lower than 2, and a degree of sulfate-group substitution of 40% by weight relative to the total weight of the over- sulfated depolymerized EPS.
  • the subject to be treated with a pharmaceutical composition described herein is a cancer patient, as described above.
  • the cancer to be prevented or treated is as described above.
  • Figure 1 Results of MTT tests on the proliferation of the MNNG-HOS human osteosarcoma cell line cultured in the presence of different infeman derivatives and control compounds.
  • Figure 7 Effect of different infeman derivatives and of control compounds on the proliferation of the A375 human melanoma cell line by xCELLigence.
  • Figure 8 Effects of Heparin, MAPI and MAP4, alone or in combination with doxorubicin on the viability of cells from (A) the MNGG-HOS human osteosarcoma cell line, and (B) the Caco2 human colon cancer cell line.
  • FIG. 11 Genes expressed by cells of the A549 human non-small cell lung cancer cell line and modulated by (A) MAPI and (B) MAP4. Total of 794 genes.
  • Figure 14 Therapeutic efficacy of MAP4 on A549 human lung cancer injected subcutaneously in nude mouse model.
  • the term ' subject refers to a human or another mammal (e.g., primate, dog, cat, goat, horse, pig, mouse, rat, rabbit, and the like), that can develop a cancer, but may or may not be suffering from the disease.
  • Non-human subjects may be transgenic or otherwise modified animals.
  • the subject is a human being.
  • the subject is often referred to as an "individual " or a "patient ". These terms do not denote a particular age, and thus encompass new-borns, children, teenagers, and adults.
  • the term ‘"patient” more specifically refers to an individual suffering from a disease.
  • cancer patient refers to an individual suffering from a cancer.
  • a cancer patient may or may not have been diagnosed with cancer.
  • the term also includes individuals who have previously undergone therapy for cancer.
  • cancer refers to or describes the physiological condition in mammals that is typically characterized by unregulated cell growth, lack of differentiation and ability to invade local tissues and metastasize. Cancer can develop in any tissue of any organ. Examples of cancers include, but are not limited to carcinoma, lymphoma, blastoma, sarcoma, and leukemia.
  • cancers include bone cancer, lung cancer, liver cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, rectal cancer, stomach cancer, colon cancer, breast cancer, carcinoma of the sexual and reproductive organs (uterine cancer, ovarian cancer, prostate cancer, etc.), Hodgkin’s Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the bladder, cancer of the kidney, renal cell carcinoma, carcinoma of the pelvis, neoplasms of the central nervous system (CNS), neuroectodermal cancer, spinal axis tumors, glioma, meningioma, and pituitary adenoma.
  • CNS central nervous system
  • invasive and invasive are used herein interchangeably. When used herein to characterize a cancer, they refer to the proclivity of a tumor for expanding beyond its boundaries into adjacent tissue. Invasive cancer can be contrasted with organ- confined cancer wherein the tumor is confined to a particular organ.
  • the invasive property of a tumor is often accompanied by the elaboration of proteolytic enzymes, such as collagenases, which degrade matrix material and basement membrane material to enable the tumor to expand beyond the confines of the capsule, and beyond confines of the particular tissue in which that tumor is located.
  • metastasis ' refers to the spread of tumor cells from one organ or tissue to another location.
  • the term also refers to tumor tissue that forms in a new location as a result of metastasis.
  • a “metastatic cancer” is a cancer that spreads from its original, or primary, location, and may also be referred to as a “secondary cancer” or “secondary tumor”.
  • metastatic tumors are named for the tissue of the primary tumor from which they originate.
  • the process of tumor metastasis is a multistage event involving local invasion and destruction of intercellular matrix, intravasation into blood vessels, lymphatics or other channels of transport, survival in the circulation, extravasation out of the vessels in the secondary site and growth in the new location.
  • the term “inhibit” means to prevent something from happening, to delay occurrence of something happening, and/or to reduce the extent or likelihood of something happening.
  • the terms “inhibiting metastasis”, “inhibiting metastases” and “inhibiting the formation of metastases”, which are used herein interchangeably, are intended to encompass preventing, delaying, and/or reducing the likelihood of occurrence of metastases as well as reducing the number, growth rate, size, etc. of metastases.
  • treatment is used herein to characterize a method or process that is aimed at (1) delaying or preventing the onset of a disease or condition (here a cancer); (2) slowing down or stopping the progression, aggravation, or deterioration of the symptoms of the disease or condition; (3) bringing about amelioration of the symptoms of the disease or condition; or (4) curing the disease or condition.
  • a treatment may be administered after initiation of the disease or condition, for a therapeutic action.
  • a treatment may be administered prior to the onset of the disease or condition, for a prophylactic or preventive action.
  • prevention may be used.
  • a “pharmaceutical composition” is defined herein as comprising an effective amount of a 50-60 kDa over-sulfated infeman derivative described herein, and at least one pharmaceutically acceptable carrier or excipient.
  • the term “effective amount” refers to any amount of a compound, agent, or composition that is sufficient to fulfil its intended purpose(s), e.g., a desired biological or medicinal response in a cell, tissue, system or subject.
  • pharmaceutically acceptable carrier or excipient refers to a carrier medium which does not interfere with the effectiveness of the biological activity of the active ingredient(s), and which is not excessively toxic to the host at the concentration at which it is administered.
  • the term includes solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic agents, and adsorption delaying agents, and the like.
  • solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic agents, and adsorption delaying agents, and the like are well known in the art (see for example “Remington ’s Pharmaceutical Sciences”, E.W. Martin, 18 th Ed., 1990, Mack Publishing Co.: Easton, PA, which is incorporated herein by reference in its entirety).
  • the present invention provides 50-60 kDa over-sulfated derivatives derived from the native infeman EPS, that exhibit anticancer properties, and the use of the 50-60 kDa over-sulfated infernan derivatives in the prevention or treatment of cancer.
  • the over-sulfated exopolysaccharide (EPS) derivatives used in the present invention are derived from a native EPS, which is excreted by the Alteromonas inf emus strain, a mesophilic marine bacterium from a deep-sea hydrothermal environment of the Alteromonas genus.
  • EPS over-sulfated exopolysaccharide
  • Marine bacterial EPSs and derivatives thereof have some great advantages as therapeutic compounds because they can be produced at viable economic cost, in controlled conditions in agreement with Good Manufacturing Practices and they exhibit a very low risk for patients to be infected by a non-conventional transmissible agent, such as prions or emerging viruses, due to a large “species-barrier”.
  • Marine bacteria from deep-sea hydrothermal vent environments belonging to three main genera (Vibrio, Alteromonas and Pseudoalteromonasf have demonstrated their ability to produce unusual extracellular polymers in an aerobic carbohydrate- supplemented medium.
  • the strain GY785 named A Iteromonas inf emus was isolated from a sample of fluid collected among a dense population of Riftia pachyptila, in the vicinity of an active hydrothermal vent of the Southern depression of the Guaymas basin (Gulf of California) (Raguenes et al., J. Appl. Microbiol., 1997, 82(4): 422-430); and the native EPS excreted by the strain GY785 has been described (Guezennec et al., Carbohydr. Polym., 1998, 37: 19-24).
  • a subsequent step consisting of sulfation of the depolymerized EPS to obtain an over-sulfated depolymerized EPS comprising adding to the depolymerized EPS at least one sulfation agent in an amount sufficient to obtain an over-sulfated polysaccharide having a degree of sulfate-group substitution of between 35% and 45% by weight relative to the total weight of the over- sulfated depolymerized EPS, preferably about 40% by weight relative to the total weight of the over-sulfated depolymerized EPS; and
  • a subsequent step consisting of isolating the 50-60 kDa over-sulfated EPS from the over-sulfated depolymerized EPS, wherein the 50-60 kDa over-sulfated EPS has a molecular weight of about 60,000 g/mol, and a poly dispersity index lower than 5, preferably comprised between 1,5 and 4, more preferably lower than 2.
  • the depolymerized EPS obtained at the end of step (a) is lyophilized.
  • step (b) of the process is followed by a dialysis step.
  • the native infernan EPS can be used in a liquid form, i.e. , as it is excreted by the bacteria into the culture medium.
  • the culture medium is centrifuged and only the supernatant containing the native infernan EPS and that is free of bacterial debris is collected.
  • the native infernan EPS can be collected by any suitable technique known to those skilled in the art, such as for example membrane ultrafiltration.
  • the native infernan EPS can then optionally be lyophilized as is or in the form of an addition salt.
  • the step consisting of free -radical depolymerization (step (a)) of the native infernan EPS is preferably carried out by adding a solution of an oxidizing agent to a reaction mixture comprising the native infernan EPS, preferably in the presence of a metal catalyst.
  • the oxidizing agent is preferably chosen from peroxides, in particular hydrogen peroxide, and peracids, especially peracetic acid and 3 -chloroperbenzoic acid.
  • the addition is preferably carried out continuously and with stirring for a period of between 30 minutes and 10 hours.
  • the reaction mixture is preferably maintained at a pH of between 6 and 8, for example by addition of a basifying agent such as sodium hydroxide, and at a temperature of between approximately 30°C and 70°C throughout the duration of the free-radical depolymerization reaction.
  • a basifying agent such as sodium hydroxide
  • the native inf eman EPS is present in the reaction mixture at a concentration of between about 2 mg/ml and about 10 mg/ml of reaction mixture.
  • the oxidizing agent is a solution of hydrogen peroxide (H2O2) preferably having a concentration of between about 0.1% and about 0.5% by weight, preferably of the order of 0.1% to 0.2% by weight, and is added at a flow rate of VI/1000 to VI/10 mL/minute, preferably VI/50 and VI/500 mL/minute, and more preferably of the order of VI/100 mL/minute, wherein VI is the volume of the reaction medium containing a marine exopolysaccharide (EPS) to which a solution of hydrogen peroxide is added.
  • H2O2 hydrogen peroxide
  • the metal catalysts that can be used during the free-radical depolymerization step are preferably chosen from Cu 2+ , Fe 2+ and Cr 3+ ions and the CnO? 2 ’ anion, as described in particular in patent application EP 0 221 977.
  • the metal catalyst is present in the reaction mixture at a concentration of between about 10' 3 M and about 10' 1 M, and preferably at a concentration of between about 0.001 M and about 0.05 M.
  • the free -radical depolymerization process according to the invention and as described above makes it possible to obtain, in a single step and with a good yield, homogeneous, lower-molecular-weight polysaccharide derivatives (5,000 to 100,000 g/mol).
  • the term “homogeneous derivatives” is intended to mean derivatives which, when assessed using high performance size exclusion chromatography, exhibit a single main peak representing a predominant population of polysaccharide chains that are homogeneous with respect to size, characterized by a polydispersity index (I) ⁇ 5.
  • the polydispersity index (I) which is a measure of the molecular mass of the derivatives, is calculated as the weight average molecular weight (Mw) divided by the number average molecular weight (Mn).
  • the depolymerized EPSs obtained are reduced using a reducing agent, so as to stabilize the chains, the reducing ends of which are very reactive, and in particular to avoid chain hydrolysis by the “peeling” reaction.
  • a reducing agent may be sodium borohydride.
  • the metal catalyst used in the free -radical depolymerization step can be eliminated at the end of the depolymerization reaction, using any suitable method, for example by ion exchange chromatography, preferably a weak cation exchange resin passivated beforehand, or by treatment with EDTA (ethylenediaminetetraacetic acid).
  • ion exchange chromatography preferably a weak cation exchange resin passivated beforehand
  • EDTA ethylenediaminetetraacetic acid
  • the depolymerized EPSs resulting from the free-radical depolymerization and/or from the reduction step can, if necessary, be recovered using any suitable technique well known to those skilled in the art, such as, for example, by membrane ultrafiltration or dialysis. Then, they are lyophilized and fractionated by size exclusion chromatography to increase their purity, which is required to improve the subsequent sulfation step. Finally, the purified depolymerized EPSs are conditioned in salt form by addition of a weak or strong base that may be chosen, for example, from pyridine, triethylamine, tributylamine, tetrabutylammonium hydroxide and sodium hydroxide.
  • a weak or strong base may be chosen, for example, from pyridine, triethylamine, tributylamine, tetrabutylammonium hydroxide and sodium hydroxide.
  • This lyophilized salt may be prepared, for example, by elution of an aqueous solution of the polysaccharide derivatives at a concentration of between 1 and 8 mg/ml on an ion exchange resin column such as, for example, those sold under the name DOWEX® by the company Dow Chemical.
  • the eluate is collected as long as the pH remains acid, for example less than 5, then the pH is subsequently adjusted to approximately 6.5 with the desired base as defined above.
  • the EPS derivatives in the form of a salt are then ultrafiltered and lyophilized.
  • the lyophilized EPS derivatives are preferably dissolved in an anhydrous solvent at the beginning of the sulfation step (step (b)).
  • the solvent is preferably chosen from dimethylformamide (DMF), dimethyl sulfoxide (DMSO) formamide, and mixtures thereof.
  • concentration of EPS derivatives present in the anhydrous solvent may be between approximately 1 and 10 mg/mL, preferably between about 1 mg/mL and about 5 mg/mL, and even more preferably this amount is about 2.5 mg/mL.
  • the dissolution of the EPS in the anhydrous solvent is preferably conducted, with stirring, at ambient temperature for about 1 hour to about 2 hours and then at a temperature of between 40°C and 50°C, preferably at a temperature of about 45 °C for about 2 hours under argon or azote with molecular sieves.
  • the one or more chemical sulfation agents used during the sulfation step can be added to the depolymerized and/or reduced EPSs that are in lyophilized form or in the form of a solution.
  • the sulfation agents are preferably chosen from complexes of pyridine sulfate (free or coupled to a polymer), of dimethylformamide sulfate, triethylamine sulfate and of trimethylamine sulfate.
  • the one or more chemical sulfation agents are added to the solution of EPS derivatives in a weight amount preferably representing from about 4 to about 6 times, and even more preferably about 5 times, the mass of EPS derivatives in solution.
  • the chemical sulfation reaction is then preferably carried out with stirring for a period of between 2 and 24 hours depending on the desired degree of sulfation.
  • the sulfation reaction is stopped after cooling of the reaction medium: either by precipitation in the presence of sodium chloride/saturated acetone or of methanol, and then dissolution of the precipitate in water; or, preferably, by addition of water in a proportion preferably equal to 1/10 of the reaction volume and adjustment of the pH of the reaction medium to 9 with a basifying agent such as, for example, sodium hydroxide (3 M).
  • a basifying agent such as, for example, sodium hydroxide (3 M).
  • the chemical sulfation reaction is continued until the degree of sulfation (or degree of sulfate-group substitution) reaches a value comprised between 35% and 45% by weight relative to the total weight of the oversulfated depolymerized EPS, for example about 35%, or about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, or about 45% by weight relative to the total weight of the over-sulfated depolymerized EPS.
  • the chemical sulfation reaction is continued until the degree of sulfation reaches a value of about 40% by weight relative to the total weight of the over- sulfated depolymerized EPS, i.e., about 38%, about 39%, about 40%, about 41%, or about 42% by weight relative to the total weight of the over-sulfated depolymerized EPS. In certain embodiments, the chemical sulfation reaction is continued until the degree of sulfation reaches a value of 40% by weight relative to the total weight of the oversulfated depolymerized EPS.
  • the solution of over-sulfated EPS derivatives is preferably dialyzed in order to remove the various salts, and then lyophilized.
  • the final product (the 60kDa over-sulfated EPS), typically with an accurate molecular weight and a low poly dispersity index, is obtained by isolation from the over- sulfated depolymerized EPS obtained in step (b).
  • Isolation (step (c)) may be performed by any suitable method known in the art. Preferably, isolation is carried out by fractionation performed by size exclusion chromatography.
  • the 50-60 kDa over-sulfated EPS (called MAP4) obtained after isolation (step (c)), has a low polydispersity index of less than 5, preferably a polydispersity index comprised betweenl.5 to 4, more preferably a polydispersity index of less than 2.
  • MAP4 polydispersity index obtained after isolation (step (c)
  • the molecular weight of a 50-60 kDa over-sulfated EPS may be about 50,000 g/mol, about 51,000 g/mol, about 52,000 g/mol, about 53,000 g/mol, about 54,000 g/mol, about 55,000 g/mol, about 56,000 g/mol, about 57,000 g/mol, about 58,000 g/mol, about 59,000 g/mol, or about 60,000 g/mol.
  • the 50-60 kDa over-sulfated EPS is an over-sulfated EPS, as defined herein, having a molecular weight of about 60,000 g/mol, a polydispersity index lower than 2, and a degree of sulfate-group substitution of 40% by weight relative to the total weight of the over-sulfated depolymerized EPS.
  • the present invention relates to a drug combination for use in the prevention or treatment of a cancer in a subject, wherein the drug combination comprises, or consists of, a 50-60 kDa over-sulfated EPS as described herein and an anticancer agent.
  • the 50-60 kDa over-sulfated EPS present in a drug combination according to the invention is an over- sulfated EPS, as defined herein, having a molecular weight of about 60,000 g/mol, a polydispersity index lower than 2, and a degree of sulfate-group substitution of 40% by weight relative to the total weight of the over-sulfated depolymerized EPS.
  • anticancer agent refers to a molecule capable of inhibiting cancer cell function.
  • the agent may inhibit proliferation or may be cytotoxic to cells.
  • a variety of anticancer agents can be used and include those that inhibit protein synthesis and those that inhibit expression of certain genes essential for cellular growth or survival.
  • Anticancer agents include those that result in cell death and those that inhibit cell growth, proliferation and/or differentiation.
  • the anticancer agent in a drug combination according to the present invention is doxorubicin.
  • Doxorubicin is an antibiotic derived from the Streptomyces peucetius bacterium. It is sold under the brand name ADRIAMYCIN® among others. It is part of the anthracycline group of chemotherapeutic agents. Doxorubicin may be used to treat soft tissue and bone sarcomas and cancers of the breast, ovary, bladder, and thyroid. It is also used to treat acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, and small cell lung cancer.
  • doxorubicin The primary mechanism of action of doxorubicin involves the drug’s ability to intercalate within DNA base pairs, causing breakage of DNA strands and inhibition of both DNA and RNA synthesis.
  • Doxorubicin inhibits the enzyme topoisomerase II, causing DNA damage and induction of apoptosis.
  • the anticancer agent in a drug combination according to the present invention is, like doxorubicin, an anthracycline.
  • Anthracyclines are a class of chemotherapy drugs that are extracted from Streptomyces bacterium. Examples of anthracyclines include, but are not limited to, daunorubicin (a doxorubicin precursor), epirubicin (a doxorubicin stereoisomer), and idarubicin (a daunorubicin derivative), which are, with doxorubicin, the most clinically important anthracyclines.
  • Other clinically used drugs in the anthracycline group are pirarubicin and aclarubicin (also known as aclacinomycin A).
  • the anticancer agent in a drug combination according to the present invention is, like doxorubicin, a DNA intercalating agent.
  • DNA intercalation can be defined as the process by which compounds containing planar aromatic or heteroaromatic ring systems are inserted between adjacent base pairs perpendicularly to the axis of the helix and without disturbing the overall stacking pattern due to Watson-Crick hydrogen bonding.
  • DNA intercalators used in the treatment of cancer include anthracyclines (see above), mitoxantrone, and dactinomycin.
  • Mitoxantrone is an anthracycline derivative that is mainly used in the treatment of acute myeloid leukemia.
  • Dactinomycin (or actinomycin D) is a member of the actinomycin family of compounds, which was isolated from several Streptomyces strains. It is used in the treatment of Wilms tumor, rhabdomyosarcoma, Ewing’s sarcoma, trophoblastic neoplasm, testicular cancer, and certain types of ovarian cancer.
  • the anticancer agent in a drug combination according to the present invention is, like doxorubicin, a topoisomerase II inhibitor.
  • Topoisomerase II forms a homodimer that functions by cleaving double stranded DNA, winding a second DNA duplex through the gap, and re-ligating the strands.
  • Topoisomerase II is necessary for cell proliferation and is abundant in cancer cells, which make topoisomerase II inhibitors effective anti-cancer treatments.
  • Topoisomerase II inhibitors are divided into two main classes: poisons and catalytic inhibitors.
  • An anticancer agent in a drug combination according to the present invention is preferably, like doxorubicin, a topoisomerase II poison.
  • Topoisomerase II poisons are characterized by their ability to create covalent bonds with DNA. Topoisomerase II poisons are divided into two groups: intercalating and non-intercalating poisons. Thus, the anticancer agent in a drug combination according to the present invention may be, an intercalating topoisomerase II poison or a non-intercalating topoisomerase II poison. Intercalating topoisomerase II poisons are mainly found in the anthracycline family (see above).
  • the 50-60 kDa oversulfated EPS and the anticancer agent, as defined above are generally present in a molar or mass ratio which are sufficient to achieve the desired goal (z.e., a preventive or therapeutic action).
  • a molar or mass ratio which are sufficient to achieve the desired goal (z.e., a preventive or therapeutic action).
  • One skilled in the art knows how to determine such molar or mass ratios.
  • a drug combination according to the present invention may comprise the 50-60 kDa over-sulfated EPS and doxorubicin in a mass ratio ranging from 100:0.0001 (w/w) to 100:10 (w/w), for example about 100:0.0001 (w/w), or about 100:0.001 (w/w), or about 100:0.01 (w/w) or about 100:0.01 (w/w) or about 100:1 (w/w) or about 100:10 (w/w).
  • a 50-60 kDa over-sulfated infernan derivative according to the present invention may be used in the prevention or treatment of a cancer in a subject.
  • a prevention or treatment of a cancer in a subject according to the present invention may be accomplished using a 50-60 kDa over-sulfated EPS or a drug combination thereof, as described herein, or a pharmaceutical composition thereof.
  • These methods generally comprise administration of an effective amount of a 50-60 kDa over-sulfated EPS, as described herein, or of a drug combination thereof or of a pharmaceutical composition thereof, to a subject in need thereof. Administration may be performed using any of the methods known to one skilled in the art.
  • a 50-60 kDa over-sulfated EPS, as described herein, or a drug combination or pharmaceutical composition thereof may be administered by any of various routes including, but not limited to, aerosol, parenteral, oral or topical route.
  • the subject is a cancer patient, preferably a human cancer patient.
  • the cancer patient may be suffering from a cancer or having previously undergone therapy of cancer.
  • the cancer patient suffering from a cancer may be undergoing therapy for cancer.
  • the cancer may be any cancer developed in any tissue of any organ.
  • the cancer may be a carcinoma, lymphoma, blastoma, sarcoma, or leukemia.
  • cancers include, but are not limited to, bone cancer, lung cancer, liver cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, rectal cancer, stomach cancer, colon cancer, breast cancer, carcinoma of the sexual and reproductive organs (uterine cancer, ovarian cancer, prostate cancer, etc.), Hodgkin’s Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the bladder, cancer of the kidney, renal cell carcinoma, carcinoma of the pelvis, neoplasms of the central nervous system (CNS), neuroectodermal cancer, spinal axis tumors, glio
  • CNS central nervous system
  • the cancer is a solid malignant tumor.
  • the solid cancer may be selected from the group consisting of osteosarcoma, non-small cell lung cancer, melanoma, colon cancer and breast cancer.
  • the cancer is metastatic cancer.
  • a 50-60 kDa over-sulfated EPS, or a drug combination thereof, or a pharmaceutical composition thereof, as described herein is administered to a patient with advanced cancer and presenting thromboembolic episodes often increased by chemotherapy and by the use of a central venous catheter.
  • a 50-60 kDa over-sulfated EPS, or a drug combination thereof, or a pharmaceutical composition thereof, as described herein will be administered in an effective amount, i.e., an amount that is sufficient to fulfill its intended purpose.
  • the exact amount to be administered will vary from subject to subject, depending on the age, sex, weight and general health condition of the subject to be treated, the desired biological or medical response and the like.
  • an effective amount is one that delays or prevents the onset of cancer, and/or one that slows down or stops the progression, aggravation, or deterioration of the symptoms of cancer, and/or one that brings about amelioration of the symptoms of cancer, and/or one that prevents, delays and/or reduces the likelihood of occurrence of metastases formation and/or one that reduces the number, growth rate, size, etc. of metastases if metastases are already present in the subject.
  • the effects of a treatment according to the invention may be monitored using any of the diagnostic assays, tests and procedures known in the art.
  • a 50-60 kDa over-sulfated EPS, or a drug combination thereof, or a pharmaceutical composition thereof, as described herein is administered alone in a method of prevention or treatment according to the present invention.
  • the 50-60 kDa over-sulfated EPS, or a drug combination thereof, or a pharmaceutical composition thereof, as described herein is administered in combination with at least one additional therapeutic agent or therapeutic procedure.
  • the 50-60 kDa over-sulfated EPS, or a drug combination thereof, or a pharmaceutical composition thereof, as described herein may be administered prior to the therapeutic procedure or administration of the therapeutic agent, concurrently with the therapeutic agent or procedure, and/or following the therapeutic procedure or administration of the therapeutic agent.
  • Therapeutic agents that may be administered in combination with the 50-60 kDa over-sulfated EPS, or a drug combination thereof, or a pharmaceutical composition thereof may be selected among a large variety of biologically active compounds that are known to have a beneficial effect in the treatment of cancer or to a patient in general (e.g., anticancer agents, anti-inflammatory agents, immunomodulatory agents, analgesics, antimicrobial agents, antibacterial agents, antibiotics, antioxidants, antiseptic agents, and combinations thereof).
  • Therapeutic procedures that may be performed in combination with administration of the 50-60 kDa over-sulfated EPS, or a drug combination thereof, or a pharmaceutical composition thereof include, but are not limited to, surgery, radiotherapy, and the like.
  • Anticancer agents that may be administered in combination with the 50-60 kDa over-sulfated EPS, or a drug combination thereof, or a pharmaceutical composition thereof, include drugs conventionally classified in one of the following group: alkylating agents, purine antagonists, pyrimidine antagonists, plant alkaloids, intercalating antibiotics, aromatase inhibitors, anti-metabolites, mitotic inhibitors, growth factor inhibitors, cell cycle inhibitors, topoisomerase inhibitors, biological response modifiers, anti-hormones and anti-androgens.
  • alkylating agents include drugs conventionally classified in one of the following group: alkylating agents, purine antagonists, pyrimidine antagonists, plant alkaloids, intercalating antibiotics, aromatase inhibitors, anti-metabolites, mitotic inhibitors, growth factor inhibitors, cell cycle inhibitors, topoisomerase inhibitors, biological response modifiers, anti-hormones and anti-androgens.
  • anticancer agents include, but are not limited to, BCNU, cisplatin, gemcitabine, hydroxyurea, paclitaxel, temozolomide, topotecan, fluorouracil, vincristine, vinblastine, procarbazine, decarbazine, altretamine, methotrexate, mercaptopurine, thioguanine, fludarabine phosphate, cladribine, pentostatin, cytarabine, azacitidine, etoposide, teniposide, irinotecan, docetaxel, doxorubicin, daunorubicin, dactinomycin, idarubicin, plicamycin, mitomycin, bleomycin, tamoxifen, flutamide, leuprolide, goserelin, aminogluthimide, anastrozole, amsacrine, asparaginase, mitoxantrone, mitot
  • anticancer agents include therapeutic antibodies used in the treatment of cancer, including, but are not limited to, anti-CD52 antibodies such as alemtuzumab (CAMPATHTM), which is used in the treatment of chronic lymphocytic leukemia; anti-VEGF antibodies including bevacizumab (AVASTINTM) which is used in the treatment of colorectal cancer and breast cancer; anti-CD33 antibodies, including gemtuzumab ozogamicin (MYLOTARGTM) which is used in the treatment of acute myeloid leukemia; anti-CD20 antibodies including ibritumomab (ZEVALINTM) which is used in the treatment of lymphoma, rituximab (RITUXANTM) which is used in the treatment of Hodgkin lymphoma, tositumomab (BEXXARTM) which is used in the treatment of Hodgkin lymphoma and of ofatumumab (ARZERRATM) which is used in the treatment of chronic lymph
  • a 50-60 kDa over-sulfated EPS, or a drug combination thereof, (optionally after formulation with one or more appropriate pharmaceutically acceptable carriers or excipients), in a desired dosage can be administered to a subject in need thereof by any suitable route.
  • Various delivery systems are known and can be used in the practice of the present invention, including tablets, capsules, injectable solutions, encapsulation in liposomes, microparticles, microcapsules, etc.
  • Methods of administration include, but are not limited to, dermal, intradermal, intramuscular, intraperitoneal, intralesional, intravenous, subcutaneous, intranasal, pulmonary, epidural, ocular, and oral routes.
  • a 50-60 kDa over-sulfated EPS, or a drug combination thereof, or a pharmaceutical composition thereof may be administered by any convenient or other appropriate route, for example, by infusion or bolus injection, by adsorption through epithelial or mucocutaneous linings (e.g., oral, mucosa, rectal and intestinal mucosa, etc.). Administration can be systemic or local. Parenteral administration may be directed to a given tissue of the patient, such as by catheterization.
  • the 50-60 kDa over-sulfated EPS, or a drug combination thereof, or a pharmaceutical composition thereof is administered along with an additional therapeutic agent
  • the 50-60 kDa over- sulfated EPS, or drug combination thereof, or pharmaceutical composition thereof, and the therapeutic agent may be administered by the same route (e.g., intravenously) or by different routes (e.g., orally, intranasally and intravenously).
  • Administration of a 50-60 kDa over-sulfated EPS, or a drug combination thereof, or a pharmaceutical composition thereof, according to the present invention will be in a dosage such that the amount delivered is effective for the intended purpose.
  • the route of administration, formulation and dosage administered will depend upon the preventive or therapeutic effect desired, the severity of the disorder being treated, the presence of any infection, the age, sex, weight and general health condition of the patient as well as upon the potency, bioavailability and in vivo half-life of the active ingredient, the use (or not) of concomitant therapies, and other clinical factors. These factors are readily determinable by the attending physician in the course of the therapy.
  • the dosage to be administered can be determined from studies using animal models.
  • a (preventive or therapeutic) treatment according to the present invention may consist of a single dose or multiple doses.
  • administration of a 50-60 kDa oversulfated EPS, or a drug combination thereof, or a pharmaceutical composition thereof, as described herein may be constant for a certain period of time or periodic and at specific intervals, e.g., hourly, daily, weekly (or at some other multiple day interval); monthly, yearly (e.g., in a time release form).
  • the administration may occur at multiple times during a given time period, e.g., two or more times per week, two or more times per month, and the like.
  • the delivery may be continuous delivery for a period of time, e.g., intravenous delivery.
  • the 50-60 kDa over-sulfated EPS, or a drug combination thereof described herein may be administered per se or as a pharmaceutical composition.
  • the present invention provides pharmaceutical compositions comprising an effective amount of a 50-60 kDa over-sulfated EPS or a drug combination thereof and at least one pharmaceutically acceptable carrier or excipient.
  • the composition further comprises one or more additional biologically active agents.
  • a 50-60 kDa over-sulfated EPS, or a drug combination thereof, or a pharmaceutical composition thereof may be administered in any amount and using any route of administration effective for achieving the desired prophylactic or therapeutic effect.
  • the optimal pharmaceutical formulation can be varied depending upon the route of administration and desired dosage. Such formulations may influence the physical state, stability, rate of in vivo release, and rate of in vivo clearance of the administered active ingredient.
  • compositions of the present invention may be formulated in dosage unit form for ease of administration and uniformity of dosage.
  • unit dosage form refers to a physically discrete unit suited as unitary dosages for the patient to be treated. It will be understood, however, that the total daily dosage of the compositions will be decided by the attending physician within the scope of sound medical judgement.
  • sterile injectable preparations for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a non-toxic parenterally acceptable diluent or solvent, for example, as a solution in 2,3-butanediol.
  • acceptable vehicles and solvents that may be employed are water, Ringer’s solution, U.S.P. and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solution or suspending medium.
  • any bland fixed oil can be employed including synthetic mono- or di-glycerides.
  • Fatty acids such as oleic acid may also be used in the preparation of injectable formulations.
  • Sterile liquid carriers are useful in sterile liquid form compositions for parenteral administration.
  • Injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
  • Liquid pharmaceutical compositions which are sterile solutions or suspensions can be administered by, for example, intravenous, intramuscular, intraperitoneal or subcutaneous injection. Injection may be via single push or by gradual infusion. Where necessary or desired, the composition may include a local anesthetic to ease pain at the site of injection.
  • Injectable depot forms are made by forming micro-encapsulated matrices of the active ingredient in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of active ingredient to polymer and the nature of the particular polymer employed, the rate of ingredient release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations can also be prepared by entrapping the active ingredient in liposomes or microemulsions which are compatible with body tissues.
  • Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, elixirs, and pressurized compositions.
  • the liquid dosage form may contain inert diluents commonly used in the art such as, for example, water or other solvent, solubilising agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cotton seed, ground nut, com, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols, and fatty acid esters of sorbitan and mixtures thereof.
  • inert diluents commonly used in the art such as, for example
  • the oral compositions can also include adjuvants such as wetting agents, suspending agents, preservatives, sweetening, flavouring, and perfuming agents, thickening agents, colors, viscosity regulators, stabilizes or osmo-regulators.
  • suitable liquid carriers for oral administration include water (potentially containing additives as above, e.g., cellulose derivatives, such as sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols such as glycols) and their derivatives, and oils (e.g., fractionated coconut oil and arachis oil).
  • the liquid carrier can be halogenated hydrocarbon or other pharmaceutically acceptable propellant.
  • the 50-60 kDa over-sulfated EPS described herein can be associated to absorption enhancers (e.g., nonionic surfactants such as alkylglycosides).
  • absorption enhancers e.g., nonionic surfactants such as alkylglycosides.
  • the 50-60 kDa over-sulfated EPS described herein can be formulated as aerosol particles or droplets or nano vectors.
  • Solid dosage forms for oral administration include, for example, capsules, tablets, pills, powders, and granules.
  • the 50-60 kDa over-sulfated EPS described herein, or a drug combination thereof may be mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and one or more of: fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid; binders such as, for example, carboxymethylcellulose, alginates, gelatine, polyvinylpyrrolidone, sucrose, and acacia; humectants such as glycerol; disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; solution retarding agents such as paraffin; absorption accelerators such as quaternary ammonium compounds; wetting agents such as,
  • excipients suitable for solid formulations include surface modifying agents such as non-ionic and anionic surface modifying agents.
  • surface modifying agents include, but are not limited to, poloxamer 188, benzalkonium chloride, calcium stearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, colloidal silicon dioxide, phosphates, sodium dodecylsulfate, magnesium aluminum silicate, and triethanolamine.
  • the dosage form may also comprise buffering agents.
  • Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatine capsules using such excipients as lactose or milk sugar as well as high-molecular-weight polyethylene glycols and the like.
  • the solid dosage forms of tablets, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition such that they release the active ingredient(s) only, or preferably, in a certain part of the intestinal tract, optionally, in a delaying manner.
  • Examples of embedding compositions which can be used include polymeric substances and waxes.
  • an inventive composition may be desirable to administer an inventive composition locally to a specific area. This may be achieved, for example, and not by way of limitation, by local infusion during surgery, topical application, by injection, by means of a catheter, by means of suppository, or by means of a skin patch or stent or another implant.
  • the composition is preferably formulated as a gel, an ointment, a lotion, or a cream which can include carriers such as water, glycerol, alcohol, propylene glycol, fatty alcohols, triglycerides, fatty acid esters, and mineral oil.
  • carriers such as water, glycerol, alcohol, propylene glycol, fatty alcohols, triglycerides, fatty acid esters, and mineral oil.
  • Other topical carriers include liquid petroleum, isopropyl palmitate, polyethylene glycol, ethanol (95%), polyoxyethylenemonolaurat (5%) in water, or sodium lauryl sulfate (5%) in water.
  • Other materials such as antioxidants, humectants, viscosity stabilizers, and similar agents may be added as necessary.
  • inventive compositions may be disposed within transdermal devices placed upon, in, or under the skin.
  • transdermal devices include patches, implants, and injections which release the active ingredient(s) by either passive or active release mechanisms.
  • Transdermal administrations include all administration across the surface of the body and the inner linings of bodily passage including epithelial and mucosal tissues. Such administrations may be carried out using the present compositions in lotions, creams, foams, patches, suspensions, solutions, and suppositories (rectal and vaginal).
  • Transdermal administration may be accomplished through the use of a transdermal patch containing an active ingredient (i.e., a 50-60 kDa over-sulfated EPS or a drug combination thereof, as described herein) and a carrier that is non-toxic to the skin, and allows the delivery of the ingredient(s) for systemic absorption into the bloodstream via the skin.
  • the carrier may take any number of forms such as creams and ointments, pastes, gels, and occlusive devices.
  • the creams and ointments may be viscous liquids or semisolid emulsions of either the oil-in-water or water-in-oil type.
  • Pastes comprised of absorptive powders dispersed in petroleum or hydrophilic petroleum containing the active ingredient may be suitable.
  • a variety of occlusive devices may be used to release the active ingredient into the bloodstream such as a semi-permeable membrane covering a reservoir containing the active ingredient with or without a carrier, or a matrix containing the active ingredient.
  • Suppository formulations may be made from traditional materials, including cocoa butter, with or without the addition of waxes to alter the suppository’s melting point, and glycerine.
  • Water soluble suppository bases such as polyethylene glycols of various molecular weights, may also be used.
  • a 50-60 kDa over-sulfated EPS, or a drug combination thereof is the only active ingredient in a pharmaceutical composition of the present invention.
  • the pharmaceutical composition further comprises one or more additional biologically active agents.
  • suitable biologically active agents include, but are not limited to, anticancer agents, anti-inflammatory agents, immunomodulatory agents, analgesics, antimicrobial agents, antibacterial agents, antibiotics, antioxidants, antiseptic agents, and combinations thereof. Examples of specific anticancer agents, including anticancer antibody agents, have been listed above.
  • the 50-60 kDa over-sulfated EPS, or the drug combination thereof, and the at least one additional biologically active agent may be combined in one or more preparations for simultaneous, separate or sequential administration of the 50-60 kDa over-sulfated EPS, or the drug combination thereof, and the biologically active agent(s).
  • an inventive composition may be formulated in such a way that the 50-60 kDa over-sulfated EPS, or the drug combination thereof, and the biologically active agent(s) can be administered together or independently from each other.
  • a 50-60 kDa over-sulfated EPS, or drug combination thereof, and a biologically active agent can be formulated together in a single composition. Alternatively, they may be maintained (e.g., in different compositions and/or containers) and administered separately.
  • the present invention provides a pharmaceutical pack or kit comprising one or more containers (e.g., vials, ampoules, test tubes, flasks or bottles) containing one or more ingredients of an inventive pharmaceutical composition, allowing administration of a 50-60 kDa over-sulfated EPS, or a drug combination thereof, of the present invention.
  • containers e.g., vials, ampoules, test tubes, flasks or bottles
  • a pharmaceutical pack or kit comprising one or more containers (e.g., vials, ampoules, test tubes, flasks or bottles) containing one or more ingredients of an inventive pharmaceutical composition, allowing administration of a 50-60 kDa over-sulfated EPS, or a drug combination thereof, of the present invention.
  • Different ingredients of a pharmaceutical pack or kit may be supplied in a solid (e.g., lyophilized) or liquid form. Each ingredient will generally be suitable as aliquoted in its respective container or provided in a concentrated form. Packs or kits according to the invention may include media for the reconstitution of lyophilized ingredients. Individual containers of the kits will preferably be maintained in close confinement for commercial sale.
  • a pack or kit includes one or more additional therapeutic agent(s).
  • associated with the container(s) can be a notice or package insert in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceutical or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.
  • the notice of package insert may contain instructions for use of a pharmaceutical composition according to methods of prevention and treatment disclosed herein.
  • An identifier e.g., a bar code, radio frequency, ID tags, etc.
  • the identifier can be used, for example, to uniquely identify the kit for purposes of quality control, inventory control, tracking movement between workstations, etc.
  • the aim of the study was to analyze the effects of different infernan derivatives on the viability and proliferation of cells of various tumor cell lines and in in vivo murine models.
  • the effects of different infernan derivatives combined to doxorubicin on the tumor cell lines were also investigated, as were the cytotoxicity and pharmacokinetic properties of the exopolysaccharides.
  • EPS exopolysaccharide
  • infernan The bacterial GY785 exopolysaccharide (EPS), named infernan, was produced, purified and characterized as previously described (Guezennec et al., Carbohydr. Polym., 1998, 37: 19-24).
  • the preparation, purification and characterization of low (LMW) and middle molecular weight (MMW) over-sulfated (OS) EPS derivatives were performed as previously reported (Ruiz Velasco et al., Glycobiology, 2011, 21: 781- 795; WO 2006/003290).
  • HMW infernan EPS native high molecular weight (HMW) infernan EPS was depolymerized first using a free-radical depolymerisation process to obtain LMW and MMW derivatives with different molecular weights.
  • Molecular weights (Mws) before and after sulfation were determined by HPSEC-MALS and sulfur content (wt% S) by HPAEC chromatography.
  • ATR-FTIR and NMR spectroscopy were used to assess the efficiency of sulfation reaction. Heparin and Dalteparin were purchased from Sigma Aldrich (Saint- Quentin Fallavier, France).
  • DR radical depolymerization step.
  • S chemical sulfation step.
  • Mw weight average molecular weight.
  • Mn number average molecular weight.
  • I polydispersity.
  • Doxorubicin was purchased from Sigma Aldrich (Saint- Quentin Fallavier, France).
  • All human tumor cell lines used in the present study were obtained from the American Tissue Cell Collection (ATCC, Molsheim, France).
  • Cells from the MNNG/HOS osteosarcoma cell line, A375 melanoma cell line, and CaCO2 colon cancer cell line were cultured with DMEM 4.5 g/E high glucose, pyruvate, non-glutamine from Gibco (Thermo-Fisher), supplemented with glutamine (Thermo-Fisher) and 5% of fetal bovine serum (FBS, Thermo-Fisher).
  • DMEM 4.5 g/E high glucose, pyruvate, non-glutamine from Gibco (Thermo-Fisher), supplemented with glutamine (Thermo-Fisher) and 5% of fetal bovine serum (FBS, Thermo-Fisher).
  • Cells from the A549 non-small cell lung cancer cell line were cultured with DEMEM/F12 (Sigma Aldrich), supplemented with glutamine (Thermo-Fisher) and 5% of fetal bovine serum (FBS, Thermo-Fisher).
  • Cells from the MDA-MB-231 breast carcinoma cell line were cultured with E-15 media from Gibco (Thermo-Fisher), supplemented with glutamine (Thermo-Fisher) and 5% of fetal bovine serum (FBS, Thermo-Fisher). All experiments were conducted at 37 °C in a humidity- saturated controlled atmosphere and 5% CO2.
  • Cell viability essay was performed by seeding, in triplicate, 3,000 cells of the indicated cell type par well (25 pL) with 25 p L of culture medium for 4 hours in a 96- well Tissue Culture Plate Flat bottom (Falcon) before adding 50 pL of a GY785 EPS derivative at concentrations of 1, 5, 10, 50, 100, 500 pg/mL and 1 mg/mL.
  • Each plate was incubated at 37°C in a humidity- saturated controlled atmosphere and 5% CO2 for 72 hours.
  • a volume of 10 pL of 5 mg/mL MTT (Sigma- Aldrich) was added and incubated for at least 3 hours at 37 °C and 5% CO2.
  • the liquid was removed and 200 pL of DMSO were added to each well to dissolve the formed formazan crystals before proceeding to the colorimetric quantification using a multi- well spectrophotometer (Victor 3x from PerkinElmer) at the wavelength of 500-600 nm.
  • Cell proliferation was analyzed by xCELLigence technology (Agilent). Background was measured by adding 50 pL of corresponding media into an E-Plate view 96 (Chem Agilent). Before the beginning of cell treatment, cells were seeded in triplicate at 5,000 cells per well (50 pL) for 4 hours. Then, 100 pL of the infernan derivatives were added at the concentrations of 100 and 500 pg/mL for MNNG/HOS, A549 and MDA-MB-231 cells, and 25 ad 50 pg/mL for A375 and Caco2 cells. The choice of these concentrations for each particular cell line was determined as a function of the IC50 established by the MTT assay.
  • Proliferation curves were normalized with respect to the time point of drug incorporation.
  • the plate was monitored for 100 hours (for MNNG/HOS, A549 and MDA-MB-231 cells) or 120 hours (for A375 and Caco2 cells) using a RTCA instruments (Agilent and ACEA).
  • the four infeman derivatives studied were MAPI (Mw: 20 kDa, 40% sulfation), MAP2 (Mw: 60 kDa, 10% sulfation), MAP3 (Mw: 60 kDa, 20% sulfation), and MAP4 (Mw: 60 kDa, 40% sulfation); the two control compounds were: heparin (Mw: 15 kDa, 30% sulfation) and dalteparin (Mw: 5 kDa, 30% sulfation); and the six human tumor cell lines were: MNNG-HOS (osteosarcoma), A549 (lung cancer), MDA MB 231 (breast cancer), A375 (melanoma), Caco2 (colon cancer) and DU145 (prostatic carcinoma).
  • a range of the four infeman derivatives studied were MAPI (Mw: 20 kDa, 40% sulfation), MAP2 (Mw: 60 k
  • the xCELLigence technology allows the impact of compounds on cellular proliferation to be monitored dynamically (z.e., in real time).
  • the tests were conducted using two different concentrations: 25 pg/mL and 50 pg/mL of the four infeman derivatives (MAP2, MAP3, and MAP4).
  • Four human tumor cell lines have been studied: the A549 (lung cancer), A375 (melanoma), Caco2 (colon cancer), and DU145 (prostatic carcinoma) cell lines.
  • the results obtained for the A375 human cell line are presented on Figure 7.
  • the data were normalized (normalized cell index) with respect to the time of EPSs treatment.
  • results obtained demonstrate the ability of the infeman derivatives to inhibit the proliferation of tumor cell lines. They confirm certain observations made with the MTT method, namely that, at equal concentrations, MAP4 (a 50-60 kDa over-sulfated EPS according to the present invention) inhibits tumor cell proliferation more efficiently than the other EPS derivatives and of the controls: heparin and dalteparin for all the tumor cell lines tested except for the MDA-MD-231 breast cancer cell line for which MAPI, at the highest concentration, was found to reduce proliferation whereas MAP2, MAP3 and MAP4 only have little effect.
  • MTT method namely that, at equal concentrations, MAP4 (a 50-60 kDa over-sulfated EPS according to the present invention) inhibits tumor cell proliferation more efficiently than the other EPS derivatives and of the controls: heparin and dalteparin for all the tumor cell lines tested except for the MDA-MD-231 breast cancer cell line for which MAPI, at the highest concentration, was found to reduce proliferation
  • MTT essay was used to evaluate the effect of two infernan derivatives (MAPI and MAP4) and two control compounds (heparin and dalteparin) on the viability of cells of five tumor cell lines (MNNG-HOS (osteosarcoma), A549 (lung cancer), MDA MB 231 (breast cancer), A375 (melanoma) et Caco2 (colon cancer).
  • MNNG-HOS osteosarcoma
  • A549 lung cancer
  • MDA MB 231 breast cancer
  • A375 melanoma
  • et Caco2 colon cancer
  • the results obtained show that the MAP4/doxorubicin combination inhibits the viability of cells from all the other tumor cell lines tested to a greater extent than the MAP4 or MAPI alone. In contrast, the MAPI /doxorubicin does not exhibit such an additive effect.
  • mice Male mice were injected intravenously with a solution of MAP4 at a concentration of 10 mg/kg (30 treated mice + 5 “control” mice). Blood was then collected at different times following the injection: at 15, 60, 120, 180 and 240 minutes (groups of 5 mice per time point), and the concentration of MAP4 in mice plasmas was determined. The results obtained are presented on Figure 9(A). Like heparin, dextran sulfate and other heparinoids, thanks to its high solubility, over-sulfated MAP4 was found to be rapidly eliminated (less than 4 hours) from the body. MAP4 exhibits an anticoagulant activity which can be detected in plasma. Its anticoagulant activity corresponds to its concentration in plasma, and it is no longer detected 4 hours after the i.v. injection.
  • MAP4 concentration decreases to reach, at 1440 minutes (24 hours), the concentration observed in the control group suggesting its complete elimination in the blood.
  • the dosage of the anticoagulant activity also makes possible the monitoring and quantification of MAP4, giving an almost identical profile (see Figure 9(C-D)).
  • the conversion of Xa factor activity to lU/ml was performed by considering that 0,19 IU is equivalent to 1 pg of factor Xa. This conversion was performed based on the instructions provided by Diagnostica Stago laboratories that furnished the product used.
  • the pharmacokinetic parameters of MAP4 were calculated for the two different modes of injection tested (i.v. and s.c.) and are presented in Table 2.
  • Ke elimination rate constante.
  • Cmax maximum concentration of the molecule.
  • Tmax time of the maximum concentration.
  • Tl/2 half-life.
  • AUC area under the curve corresponding to total drug exposure.
  • AUMC area under the first-order moment curve of concentration/time.
  • CL clearance.
  • Vd volume of distribution.
  • MRT AUMC/AUC average presence time.
  • F absolute bioavailability.
  • the maximum concentration (Cmax) of MAP4 in plasma was determined to be 32.8 pg/mL and 30.1 g/mL, respectively.
  • MAP4 was found to quickly reach the Cmax value and is eliminated with a short halflife.
  • MAP4 has a poor tissue distribution, and its clearance is indicative of a poor extraction. It exhibits a high solubility with a high affinity for plasma proteins, which could explain its high bioavailability after s.c. administration in mice.
  • MAPI and MAP4 were analyzed in two complementary mouse models. These models consisted in inoculating murine melanoma cells B16F10 (melanoma) and CMT167 (lung carcinoma) subcutaneously in immunocompetent C57/BL6 mice and monitoring the evolution of the tumor volume with a caliper every two days. The weight of the 8 week-old animals was monitored twice a week. MAPI and MAP4 were injected at a dose of 10 mg/kg per day, five times per week and compared with a solution of NaCl. The results, which are presented on Figure 11, show an inhibitory effect of the two infernan derivatives on tumor growth in both models studied, thus demonstrating an effect of the two compounds on the primary tumor. No apparent toxicity was observed and no impact on animal weight was reported. MAP4 was found to show a significantly greater effect than MAPI at the dose tested.
  • mice After one week of quarantine, 10 6 A549 cells were injected per female NMRI nude mouse in the right flank via s.c. (50 p.L PBS + 50 p.L matrigel). Mice were then distributed randomly in 4 groups:
  • mice NaCl, s.c., 5 times per week;
  • Doxorubicin group (8 mice): 3 mg/kg, i.v., 3 consecutive days;
  • mice Doxorubicin 3 consecutive days + MAP4 5 times per week;
  • MAP4 group (8 mice): 4 mg/kg; s.c., 5 times per week.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un exopolysaccharide sursulfaté de 50-60 kDa préparé à partir d'un exopolysaccharide natif marin, nommé infernane, excrété par une bactérie marine mésophile à partir d'un environnement hydrothermique en mer profonde (une espèce Alteromonas infernus du genre Alteromonas), et se rapporte à l'utilisation de l'exopolysaccharide sursulfaté de 50-60 kDa pour la prévention ou le traitement du cancer. L'invention concerne également une combinaison de médicaments comprenant l'exopolysaccharide sursulfaté de 50-60 kDa et un agent anticancéreux, tel que la doxorubicine, destiné à être utilisé dans la prévention ou le traitement du cancer.
PCT/EP2024/071243 2023-07-27 2024-07-26 Dérivé d'exopolysaccharide bactérien marin présentant des propriétés anticancéreuses et ses utilisations Pending WO2025021972A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP23188267.1 2023-07-27
EP23188267 2023-07-27

Publications (1)

Publication Number Publication Date
WO2025021972A1 true WO2025021972A1 (fr) 2025-01-30

Family

ID=87519803

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2024/071243 Pending WO2025021972A1 (fr) 2023-07-27 2024-07-26 Dérivé d'exopolysaccharide bactérien marin présentant des propriétés anticancéreuses et ses utilisations

Country Status (1)

Country Link
WO (1) WO2025021972A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0221977A1 (fr) 1985-05-17 1987-05-20 Opocrin Spa Sulfates d'hexosaminoglucane depolymerises dotes d'une activite antithrombotique fibrinolytique et anti-inflammatoire, leur procede de preparation et compositions pharmaceutiques associees.
WO2006003290A2 (fr) 2004-06-14 2006-01-12 Institut Francais De Recherche Pour L'exploitationde La Mer (Ifremer) Derives depolymerises sulfates d'exopolysaccharides (eps) preparation et utilisations
WO2012126824A1 (fr) * 2011-03-18 2012-09-27 Inserm (Institut National De La Sante Et De La Recherche Medicale) Milieu de différenciation chondrogène et procédé d'induction de différenciation chondrogène des cellules
EP3146971A1 (fr) * 2015-09-28 2017-03-29 Institut Francais de Recherche pour l'Exploitation de la Mer (IFREMER) Dérivé d'exopolysaccharide bactérien marin anti-métastatique et leurs utilisations
US20220160610A1 (en) * 2016-09-19 2022-05-26 Institut Univ. De Ciència I Tecnologia, S.A. Exopolysaccharide-protein complex, a method of preparing said complex and uses thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0221977A1 (fr) 1985-05-17 1987-05-20 Opocrin Spa Sulfates d'hexosaminoglucane depolymerises dotes d'une activite antithrombotique fibrinolytique et anti-inflammatoire, leur procede de preparation et compositions pharmaceutiques associees.
WO2006003290A2 (fr) 2004-06-14 2006-01-12 Institut Francais De Recherche Pour L'exploitationde La Mer (Ifremer) Derives depolymerises sulfates d'exopolysaccharides (eps) preparation et utilisations
EP1765366A2 (fr) * 2004-06-14 2007-03-28 Institut Français de Recherche pour l'Exploitation de la Mer (IFREMER) Derives depolymerises sulfates d'exopolysaccharides (eps), preparation et utilisations
WO2012126824A1 (fr) * 2011-03-18 2012-09-27 Inserm (Institut National De La Sante Et De La Recherche Medicale) Milieu de différenciation chondrogène et procédé d'induction de différenciation chondrogène des cellules
EP3146971A1 (fr) * 2015-09-28 2017-03-29 Institut Francais de Recherche pour l'Exploitation de la Mer (IFREMER) Dérivé d'exopolysaccharide bactérien marin anti-métastatique et leurs utilisations
WO2017055310A1 (fr) 2015-09-28 2017-04-06 Institut Francais De Recherche Pour L'exploitation De La Mer (Ifremer) Dérivé d'exopolysaccharide bactérien marin anti-métastatique et ses utilisations
US20220160610A1 (en) * 2016-09-19 2022-05-26 Institut Univ. De Ciència I Tecnologia, S.A. Exopolysaccharide-protein complex, a method of preparing said complex and uses thereof

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
BOBEKKOVARIK, BIOMEDICINE & PHARMACOTHERAPY, vol. 2004, no. 58, pages 213 - 219
COLLIEC JOUAULT S. ET AL., BIOCHIM. BIOPHYS. ACTA, vol. 1528, no. 1528, 2001, pages 141 - 151
COLLIEC-JOUAULT ET AL., BIOMACROMOLECULE, vol. 2023, no. 24, pages 462 - 470
COLLIEC-JOUAULT ET AL.: "Handbook of Exp. Pharmacol.", 2012, pages: 423 - 449
DEANGELIS, APPL. MICROBIOL. BIOTECHNOL., vol. 2012, no. 94, pages 295 - 305
E.W. MARTIN: "Remington's Pharmaceutical Sciences", 1990, MACK PUBLISHING CO.
GUEZENNEC ET AL., CARBOHYDR. POLYM., vol. 1998, no. 37, pages 19 - 24
GUEZENNEC J. ET AL., CARBOHYDRATE POLYMERS, vol. 1998, no. 37, pages 19 - 24
LANZICASSINELLI, MOLECULES, vol. 23, no. 11, 2018, pages 2915
RAGUÉNÈS ET AL., J. APPL. MICROBIOL., vol. 82, no. 4, 1997, pages 422 - 430
REHM ET AL., REV. MICROBIOL., vol. 2010, no. 8, pages 578 - 592
ROGER ET AL., CARBOHYDR. RES., vol. 2004, no. 339, pages 2371 - 2380
RUIZ VELASCO ET AL., GLYCOBIOLOGY, vol. 2011, no. 21, pages 781 - 795
SASISEKHARAN ET AL., NAT. REV. CANCER, vol. 2002, no. 2, pages 521 - 528
STEVENSON ET AL., RESEARCH, vol. 2007, no. 120, pages S107 - S111
VELASCO ET AL., DRUG DISCOV. TODAY, vol. 2010, no. 15, pages 553 - 560
VISMARA ET AL., MOLECULES, vol. 2010, no. 15, pages 5096 - 5103

Similar Documents

Publication Publication Date Title
CN102300870B (zh) 低分子量多硫酸化透明质酸衍生物和含有它的医药
JP4514240B2 (ja) 硫酸化オリゴ糖の製造および使用
KR100855331B1 (ko) 혈관형성 억제 활성을 가지며 응고억제 효과는 없는,헤파라나제 억제제로서 부분적으로 탈황산화된글리코스아미노글리칸의 유도체
JP2001527583A (ja) ヘパリンのｏ−脱硫酸化の制御方法およびそれによって得られる組成物
EP3355897B1 (fr) Dérivé d'exopolysaccharide bactérien marin anti-métastatique et ses utilisations
US11225531B2 (en) Glycosaminoglycan derivative and preparation method therefor and use thereof
CN105814086B (zh) N-脱硫酸化糖胺聚糖的衍生物以及作为药物的用途
WO2025021972A1 (fr) Dérivé d'exopolysaccharide bactérien marin présentant des propriétés anticancéreuses et ses utilisations
US20240424015A1 (en) Low-Molecular-Weight HE800 Exopolysaccharide Derivatives with Anti-Cancer Properties and Uses Thereof
CN1067245C (zh) N－乙酰－d－氨基葡萄糖在制备治疗呼吸道疾病的药物中的应用
US8778892B2 (en) Compounds and methods for treatment of solid tumors
CA3187652A1 (fr) Derives d'exopolysaccharides bacteriens d'origine marine et leurs utilisations dans le traitement de mucopolysaccharidoses
CN101267828A (zh) 用于共同递送抗癌药、抗血管生成药和多糖的组合物及方法
KR20250019674A (ko) 화학적으로 변형된 헤파린
JP5051999B2 (ja) 炎症性骨・軟骨疾患の処置剤
MXPA97008289A (en) Preparation and use of oligosacaridos sulfata

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24748922

Country of ref document: EP

Kind code of ref document: A1